Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
Targeted therapy has significantly prolonged survival of non-small cell lung cancer (NSCLC) patients carrying common EGFR mutations, but the standard care for patients with rare mutations has not been well established. Here, we report a 65-year-old female diagnosed with stage IIIC lung adenocarcinom...
Saved in:
Main Authors: | Yueming He (Author), Yitao Wu (Author), Rongqi He (Author), Meng Xu (Author), Heshan Chen (Author), Yiran Meng (Author), Liuqing Zheng (Author), Li Wang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021) -
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
by: Francesca Foschi, et al.
Published: (2023) -
Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR<sup>L858R/T790M</sup> Mutations
by: Moamen A. Hassanin, et al.
Published: (2022) -
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
by: Chih-Jen Yang, et al.
Published: (2017) -
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020)